CD117 (c-kit) Expression in Human Hepatocellular Carcinoma

Becker, Gerhild; Schmitt‐Graeff, Annette; Ertelt, V.; Blum, Hubert E.; Allgaier, Hans-Peter

doi:10.1016/j.clon.2006.12.009

Cited by 37 publications

(30 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD90 has been detected in high grade human glioma [76, 77], as well as liver [78] and lung tumors [79, 80]; while CD117 has been used as a CSC marker in leukemia [81, 82] and gastrointestinal stromal tumor [83], as well as oral squamous cell carcinomas [84, 85] and ovarian tumors[86, 87]. CD117 has been shown to be overexpressed in hepatocellular [88] and pancreatic carcinoma[89]. CD24 has been used in combination with CD44 in breast cancer cell lines to show that CD44+/CD24- cancer cells exhibit drug resistance and invasive properties [90-92].…”

Section: Introductionmentioning

confidence: 99%

Stemness-related markers in cancer

2017

View full text Add to dashboard Cite

Cancer stem cells (CSCs), with their self-renewal ability and multilineage differentiation potential, are a critical subpopulation of tumor cells that can drive tumor initiation, growth, and resistance to therapy. Like embryonic and adult stem cells, CSCs express markers that are not expressed in normal somatic cells and are thus thought to contribute towards a ‘stemness’ phenotype. This review summarizes the current knowledge of stemness-related markers in human cancers, with a particular focus on important transcription factors, protein surface markers and signaling pathways.

show abstract

Section: Introductionmentioning

confidence: 99%

Stemness-related markers in cancer

2017

View full text Add to dashboard Cite

show abstract

“…The value of CEC and CECP levels as biomarkers of angiogenesis and antiangiogenic therapies in HCC needs further prospective analysis. In fact, methods and techniques of measurement were inconsistent, and unreliable results were reported depending on the type of study (clinical or preclinical studies), cancer types, and antiangiogenic agents [98,115,116,121] . In summary, none of the above biomarkers is validated to predict response to sorafenib in patient with advanced HCC.…”

Section: Circulating Endothelial Cells and Circulating Endothelial Cementioning

confidence: 99%

“…Similarly, improvement of TTP and trend towards better OS were reported when soluble KIT plasma level decreased from baseline following sunitinib in patients with HCC, metastatic breast cancer and neuroendocrine tumor [93,95,101] . Nowadays, the role of soluble c-KIT in HCC pathogenesis remains unclear since the expression of this protein kinase in HCC tissue appears to be anecdotal [116] .…”

Section: Stem-cell Factor Receptor -Kitmentioning

confidence: 99%

Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging

Bouattour

Payancé

Wassermann

2015

WJH

View full text Add to dashboard Cite

Many years after therapeutic wilderness, sorafenib finally showed a clinical benefit in patients with advanced hepatocellular carcinoma. After the primary general enthusiasm worldwide, some disappointments emerged particularly since no new treatment could exceed or at least match sorafenib in this setting. Without these new drugs, research focused on optimi zing care of patients treated with sorafenib. One challenging research approach deals with identifying prognostic and predictive biomarkers of sorafenib in this population. The task still seems difficult; however appropriate investigations could resolve this dilemma, as observed for some malignancies where other drugs were used.

show abstract

“…Discussion c-kit expression plays a pathogenic role in a number of malignancies besides GIST, namely breast carcinomas, germ cell tumors, colon carcinoma, some subtypes of sarcoma, melanoma, ovarian and small cell lung carcinoma [34][35][36]. Inhibition of the c-kit and the PDGFR pathway with low-molecular-weight kinase inhibitors resulted in clinical benefits in patients with GIST [23] and dermatofibrosarcoma protuberans [37].…”

Section: Resultsmentioning

confidence: 99%

c-kit (CD117) Expression in Human Tumors and its Prognostic Value: An Immunohistochemical Analysis

Medinger

Kleinschmidt

Mross

et al. 2010

Pathol. Oncol. Res.

View full text Add to dashboard Cite

c-kit functions as a tyrosine kinase receptor and represents a target for small molecule kinase inhibitors. The expression pattern for c-kit was studied in different human tumor types to their correlation with prognosis. Paraffin-embedded tumor tissues from 282 patients were analyzed immunohistochemically for c-kit expression. Survival and follow-up data were available from 192/282 (68%) patients. c-kit immunopositivity was found in 62/282 (22%) cases. c-kit expression was found in 14/83 (17%) colorectal cancers, in 13/62 (21%) breast cancers, in 7/20 sarcomas (35%), in 5/14 (36%) renal cell carcinomas, in 2/12 ovarian cancers (17%) and in 2/12 (17%) hepatocellular carcinomas. We found no significant correlation between c-kit expression and prognosis although a trend to a worse prognosis in patients with c-kit positive tumors could be observed. Expression of c-kit was found in tumor samples with varying intensities and infrequently.

show abstract

CD117 (c-kit) Expression in Human Hepatocellular Carcinoma

Cited by 37 publications

References 41 publications

Stemness-related markers in cancer

Stemness-related markers in cancer

Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging

c-kit (CD117) Expression in Human Tumors and its Prognostic Value: An Immunohistochemical Analysis

Contact Info

Product

Resources

About